Sharemaestro company-news research for GRAIL, LLC (GRAL), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Measured evidence
Company news sentiment
GRAL news sentiment
GRAIL, LLC
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score27Neutral is 50
Cautious news tone
54/100 evidence confidence
100% direct company focus
55 current stories across 17 publishers
Current company news
Cautious news tone
The score uses 55 current company stories from 17 publishers.
Observed headline tone19/100
→
Published 30-day score27/100
Latest source headline
GRAIL Inc Revenue Breakdown – LSX:A40F8M
TradingView · 08 Aug 2026 18:40
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
55 current stories are mapped specifically to GRAL.
The score uses 17 publishers rather than depending on one outlet.
The current stories agree at 90/100.
Cautious headlines are being absorbed by price, which can signal underlying demand.
What limits the score
No major limit stands out.
27/100
News scoreCautious news tone
54/100
Confidencebuilding confidence
100%/100
Company news55 company stories
90/100
Story agreement10/100 difference
News history
Daily score and story count over 30 days
16 Jul31 Jul14 Aug
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence52
2.6 after freshness weightingSource breadth100
17 independent publishersCompany relevance100
share tied directly to this companyFreshness8
recency-weighted evidenceAgreement90
how closely stories agreePublisher mix66
less reliance on one publisherPrice and news history
News score and weekly price over 26 weeks
Cautious headlines are being absorbed by price, which can signal underlying demand.
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
07 Aug 202625USD 69.48+1.3%
31 Jul 202624USD 68.56+1.1%
24 Jul 202623USD 67.84-6.6%
17 Jul 202627USD 72.62+0.9%
10 Jul 202649USD 72.0+4.2%
03 Jul 202647USD 69.11+4.8%
26 Jun 202650USD 65.92+3.4%
Caution agrees with inactive trend
News subjects
What is shaping the score
Regulatory and legal1741 stories · 75%
Market update496 stories · 11%
Earnings506 stories · 11%
Guidance371 stories · 2%
Deals and strategy571 stories · 2%
Source mix
Where the evidence comes from
GlobeNewswire1817 stories · 31%
PR Newswire147 stories · 13%
TradingView325 stories · 9%
Stock Titan545 stories · 9%
Morningstar143 stories · 5%
The National Law Review153 stories · 5%
TMX Newsfile132 stories · 4%
Recurring subjects
Subjects appearing most often
Life Sciences52Finance47Financial Markets16Earnings10
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
22 Jun50 neutral14 Aug 07:07
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 14 Aug 07:07 | 29 | +3 | 47/100 (-14) | 56 (-3) | Measured |
| 08 Aug 23:59 | 26 | +2 | 61/100 (-9) | 59 (0) | Measured |
| 04 Aug 23:59 | 24 | +0 | 70/100 (-4) | 59 (-1) | Measured |
| 31 Jul 23:59 | 24 | -1 | 74/100 (-1) | 60 (+1) | Measured |
| 30 Jul 23:59 | 25 | +0 | 75/100 (+1) | 59 (+3) | Measured |
| 29 Jul 23:59 | 25 | +0 | 74/100 (0) | 56 (+3) | Measured |
| 28 Jul 23:59 | 25 | +1 | 74/100 (0) | 53 (+4) | Measured |
| 27 Jul 23:59 | 24 | +1 | 74/100 (-2) | 49 (+3) | Measured |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#150Tone
TradingViewDirect company coverageStored article
GRAIL Inc Revenue Breakdown – LSX:A40F8M
GRAIL Inc (LSX:A40F8M) generated 125.31 million EUR in revenue last year. The majority of this revenue, 118.01 million EUR, came from its top-performing "Screening" segment, an increase from 104.93 million EUR in the previous year. The United States was the largest geographical contributor, accounting for 116.72 million EUR in revenue.
EarningsLife Sciences
- Published
- 08 Aug 2026 18:40
- News subject
- Earnings
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 1.7% · 5.5d old
- Duplicates
- 1 consolidated
#250Tone
Market sourceDirect company coverageScored from headlineSource lookup
Is GRAIL (GRAL) Fairly Valued Following Galleri Adoption Growth And The FDA Panel Date?
- Published
- 08 Aug 2026 05:12
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 0.2% · 6.1d old
- Duplicates
- 1 consolidated
#314Tone
Eagle-TribuneDirect company coverageStored article
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026
Faruqi & Faruqi, LLP is investigating potential securities claims against Grail, Inc. (NASDAQ: GRAL) and reminds investors that the deadline to seek the role of lead plaintiff in a federal securities class action lawsuit is August 4, 2026. The lawsuit alleges that Grail made false and misleading statements regarding the success likelihood of its NHS-Galleri trial, leading to a significant stock price drop after the company announced its primary endpoint was not met. Investors who purchased GRAL stock between May 13, 2024, and February 19, 2026, and suffered losses are encouraged to contact the firm.
FinanceLife Sciences
- Published
- 04 Aug 2026 18:41
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk, Negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 6.7% · 9.5d old
- Duplicates
- 1 consolidated
#425Tone
GlobeNewswireDirect company coverageStored article
Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in Grail, Inc. (NASDAQ: GRAL) who purchased securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail made misleading statements and concealed material adverse facts regarding the true state of its NHS-Galleri trial, specifically concerning the sufficiency of the trial period to demonstrate a reduction in Stage III-IV cancers. Investors are encouraged to contact the firm to discuss their legal rights.
FinanceLife Sciences
- Published
- 04 Aug 2026 13:41
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 5% · 9.7d old
- Duplicates
- 1 consolidated
#510Tone
PR NewswireDirect company coverageStored article
GRAL DEADLINE TODAY: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL), urging investors with substantial losses to join before the August 4, 2026, lead plaintiff deadline. The lawsuit alleges that GRAIL and its executives misled investors about the NHS-Galleri cancer screening trial's design and efficacy, particularly concerning the sufficiency of its three-year follow-up period. GRAIL's stock plummeted by 50.55% on February 19, 2026, after the company disclosed that the trial failed to meet its primary endpoint and admitted to a flawed timeline, leading to over $2.2 billion in market cap loss.
Life SciencesFinancial MarketsFinance
- Published
- 04 Aug 2026 09:41
- News subject
- Regulatory and legal
- Why this score
- Failed To Meet, Legal or regulatory risk
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 6.5% · 9.9d old
- Duplicates
- 1 consolidated
#610Tone
GlobeNewswireDirect company coverageStored article
$GRAL Securities: Suffer Losses on Your GRAIL, Inc.
Bleichmar Fonti & Auld LLP has filed a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) and its executives for securities fraud. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, causing a 50% stock drop after the trial failed to meet its primary endpoint. Investors who suffered losses are encouraged to contact BFA Law before the August 4, 2026, lead plaintiff deadline.
EarningsFinanceFinancial MarketsLife Sciences
- Published
- 31 Jul 2026 06:46
- News subject
- Regulatory and legal
- Why this score
- Failed To Meet, Legal or regulatory risk, Negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 5.6% · 14.0d old
- Duplicates
- 1 consolidated
#750Tone
Stock TitanDirect company coverageStored article
GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference
GRAIL (Nasdaq: GRAL) announced that its management will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, at 10:00 a.m. ET. Live and replay webcasts of the presentation will be available through GRAIL's investor relations website, with the replay archived for at least 30 days. This event provides investors with an opportunity to learn more about GRAIL's mission to detect cancer early.
FinanceLife Sciences
- Published
- 30 Jul 2026 20:10
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 14.5d old
- Duplicates
- 2 consolidated
#825Tone
Business WireDirect company coverageStored article
GRAL Deadline: Rosen Law Firm Urges GRAIL, Inc. (NASDAQ: GRAL) Stockholders to Contact the Firm for Information About Their Rights
Rosen Law Firm is notifying stockholders of GRAIL, Inc. (NASDAQ: GRAL) about a class action lawsuit for alleged misleading statements made between May 13, 2025, and February 19, 2026. The lawsuit claims GRAIL concealed material adverse facts regarding its NHS-Galleri trial's sufficiency to demonstrate a reduction in Stage III-IV cancers. Shareholders have until August 4, 2026, to file as lead plaintiff.
Life SciencesFinance
- Published
- 30 Jul 2026 17:10
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 3.1% · 14.6d old
- Duplicates
- 1 consolidated
#925Tone
GlobeNewswireDirect company coverageStored article
Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) alleging violations of federal securities laws. The lawsuit claims that Grail and its officers made false and misleading statements regarding the likelihood of achieving the primary endpoint in Grail’s NHS-Galleri trial, thereby harming investors. Investors who purchased Grail securities between May 13, 2025, and February 19, 2026, are encouraged to join the class action, with a lead plaintiff deadline of August 4, 2026.
Life SciencesFinance
- Published
- 30 Jul 2026 16:10
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 3.1% · 14.6d old
- Duplicates
- 1 consolidated
#1014Tone
MorningstarDirect company coverageStored article
Levi & Korsinsky Reminds Grail, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 4, 2026 - GRAL
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Grail, Inc. (NASDAQ: GRAL), reminding investors who purchased stock between May 13, 2025, and February 19, 2026, of the August 4, 2026 lead plaintiff deadline. The lawsuit alleges that Grail's leadership withheld crucial internal data suggesting the NHS-Galleri trial's three-year design was insufficient to achieve its primary endpoint, leading to a significant stock price drop when the trial failed. Investors who suffered losses are encouraged to contact the firm to recover damages.
EarningsFinanceLife Sciences
- Published
- 30 Jul 2026 11:11
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk, Negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 5.4% · 14.8d old
- Duplicates
- 3 consolidated
#1150Tone
TradingViewDirect company coverageStored article
GRAIL to Announce Second Quarter 2026 Financial Results
GRAIL, Inc. (Nasdaq: GRAL) announced it will release its second-quarter 2026 financial results after market close on Wednesday, August 5, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and business progress. Interested parties can find a link to the live webcast and recorded replay on the investor relations section of GRAIL's website.
EarningsLife Sciences
- Published
- 29 Jul 2026 23:39
- News subject
- Earnings
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 0.4% · 15.3d old
- Duplicates
- 1 consolidated
#1214Tone
GlobeNewswireDirect company coverageStored article
Bragar Eagel & Squire, P.C. Reminds GRAIL, Inc. Investors They Have Until August 4th to Contact the Firm Seeking Lead Plaintiff Rol
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) for allegedly making false and misleading statements regarding its NHS Galleri trial. Investors who purchased GRAIL common stock between May 13, 2025, and February 19, 2026, and suffered losses are encouraged to contact the firm by August 4, 2026, to discuss potentially becoming lead plaintiff. The lawsuit claims GRAIL concealed issues with the trial's ability to demonstrate a reduction in Stage III-IV cancers, leading to a significant stock price drop after negative trial results were revealed on February 19, 2026.
FinanceLife Sciences
- Published
- 29 Jul 2026 22:09
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk, Negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 4.3% · 15.4d old
- Duplicates
- 2 consolidated
#1350Tone
Stock TitanDirect company coverageStored article
GRAIL webcast on Aug. 5 results open to all interested parties
GRAIL (Nasdaq: GRAL) will announce its second quarter 2026 financial results after market close on Wednesday, August 5, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and business progress. The live webcast and recorded replay will be accessible via the investor relations section of GRAIL's website, and interested participants are encouraged to register in advance.
EarningsLife Sciences
- Published
- 29 Jul 2026 20:11
- News subject
- Earnings
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 0.4% · 15.5d old
- Duplicates
- 1 consolidated
#1412Tone
GlobeNewswireDirect company coverageStored article
GRAL Court Deadline: GRAIL, Inc. Investor Deadline in Securities Fraud Class Action is August 4 – Contact BFA Law if You Lost Money
Bleichmar Fonti & Auld LLP has announced a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) and its executives. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, which caused a 50.55% stock drop on February 20, 2026, after the trial failed to meet its primary endpoint. Investors who lost money are encouraged to contact BFA Law by the lead plaintiff deadline of August 4, 2026.
EarningsFinanceFinancial MarketsLife Sciences
- Published
- 29 Jul 2026 10:17
- News subject
- Regulatory and legal
- Why this score
- Failed To Meet, Legal or regulatory risk, Negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 4.5% · 15.9d old
- Duplicates
- 1 consolidated
#1557Tone
Stock TitanDirect company coverageStored article
BlackRock (GRAL holder) discloses 7.9% GRAIL, Inc. stake in 13G/A
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 7.9% passive ownership stake in GRAIL, Inc. (GRAL). This ownership amounts to 3,376,085 shares of GRAIL common stock, with BlackRock holding sole voting power over 3,312,474 shares and sole dispositive power over all 3,376,085 shares. The filing indicates that no single client of BlackRock exceeds five percent of GRAIL's outstanding common shares.
FinanceFinancial MarketsLife Sciences
- Published
- 28 Jul 2026 21:41
- News subject
- Deals and strategy
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 0.7% · 16.4d old
- Duplicates
- 1 consolidated
#1625Tone
Carroll County Mirror-DemocratDirect company coverageStored article
Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit against Grail, Inc. (NASDAQ: GRAL) on behalf of investors who purchased securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail disseminated materially false and misleading statements regarding its NHS-Galleri trial, concealing that the trial design was insufficient to demonstrate a reduction in Stage III-IV cancers within the specified follow-up period. Investors have until August 4, 2026, to file a lead plaintiff motion.
FinanceLife Sciences
- Published
- 28 Jul 2026 15:41
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 2.2% · 16.6d old
- Duplicates
- 2 consolidated
#1740Tone
PR NewswireDirect company coverageStored article
Lost Money on GRAIL, Inc. (GRAL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
The Gross Law Firm has issued a notice to shareholders of GRAIL, Inc. (NASDAQ: GRAL) who purchased shares between May 13, 2025, and February 19, 2026. The firm encourages these shareholders to join a class action lawsuit seeking recovery, stating that the company allegedly provided false and misleading statements regarding its NHS-Galleri trial's potential to reduce Stage III-IV cancers. Following the announcement that the trial's primary endpoint was not met, GRAIL's stock price dramatically declined by over 50% in one day.
Life SciencesFinance
- Published
- 28 Jul 2026 13:41
- News subject
- Market update
- Why this score
- Legal or regulatory risk
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 16.7d old
- Duplicates
- 1 consolidated
#1844Tone
ACCESS NewswireDirect company coverageStored article
Pomerantz LLP Shares Class Action Details With Investors in GRAIL, Inc. – GRAL
Pomerantz LLP has announced a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) following a significant drop in its stock price. The lawsuit stems from Grail's announcement on February 19, 2026, that its NHS-Galleri Trial did not meet its primary endpoint, leading to a more than 50% decline in stock value. Investors who purchased Grail securities during the Class Period have until August 4, 2026, to seek appointment as Lead Plaintiff.
FinanceLife Sciences
- Published
- 28 Jul 2026 07:40
- News subject
- Regulatory and legal
- Why this score
- Legal victory, Legal or regulatory risk
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 1.5% · 17.0d old
- Duplicates
- 1 consolidated
#1925Tone
wahanariau.comDirect company coverageStored article
GRAL DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important August 4 Deadline in Securities Class Action – GRAL
Rosen Law Firm is reminding investors who purchased GRAIL, Inc. (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, about the August 4, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that GRAIL made materially false and misleading statements and/or concealed material adverse facts regarding its NHS-Galleri trial, specifically concerning its sufficiency to demonstrate a reduction in Stage III-IV cancers. Investors are encouraged to contact the Rosen Law Firm to join the class action and potentially recover damages.
Life SciencesFinance
- Published
- 27 Jul 2026 22:50
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 2.1% · 17.3d old
- Duplicates
- 1 consolidated
#2050Tone
GlobeNewswireDirect company coverageStored article
$GRAL Lawsuit Notice: BFA Law Reminds GRAIL, Inc. Investors
BFA Law has filed a securities fraud class action lawsuit against GRAIL, Inc. following a 50% stock drop. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial by making positive statements about the trial's design and results, despite the three-year timeframe being insufficient to demonstrate the primary endpoint. Investors have until August 4, 2026, to seek lead plaintiff status in the case.
FinanceLife SciencesFinancial Markets
- Published
- 27 Jul 2026 11:40
- News subject
- Regulatory and legal
- Why this score
- Legal victory, Legal or regulatory risk
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 1.2% · 17.8d old
- Duplicates
- 1 consolidated
#2113Tone
TMX NewsfileDirect company coverageStored article
AUGUST 4, 2026 GRAL DEADLINE: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces a shareholder class action lawsuit against GRAIL, Inc. and its executives for alleged Securities Exchange Act violations. The lawsuit claims that Grail made false and misleading statements regarding its NHS-Galleri trial's primary endpoint, which was not achieved, leading to a significant stock price drop. Investors who suffered substantial losses between
FinanceLife Sciences
- Published
- 27 Jul 2026 10:40
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk, Negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 3.1% · 17.9d old
- Duplicates
- 2 consolidated
#2212Tone
ACCESS NewswireDirect company coverageStored article
GRAIL, Inc. ($GRAL) Investors Notified of August 4 Court Deadline in Securities Fraud Lawsuit Over Trial Results Allegations
A class action lawsuit has been filed against GRAIL, Inc. (NASDAQ: GRAL) and its executives for securities fraud, stemming from a significant stock drop after the NHS-Galleri cancer trial failed to meet its primary endpoint. Investors have until August 4, 2026, to seek lead plaintiff status in the case, which alleges the company made misleading statements about the trial's design and results. The lawsuit claims GRAIL's stock fell over 50% following the announcement that the trial did not show a statistically significant reduction in late-stage cancers.
Life SciencesFinance
- Published
- 27 Jul 2026 03:40
- News subject
- Regulatory and legal
- Why this score
- Failed To Meet, Legal or regulatory risk, Negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 3.2% · 18.1d old
- Duplicates
- 1 consolidated
#2350Tone
TradingViewDirect company coverageStored article
GRAIL Inc Revenue Breakdown – HAN:NL0
GRAIL Inc (NL0) generated 125.31 million EUR in revenue last year. The majority of this revenue, 118.01 million EUR, came from its top segment, Screening, showing an increase from the previous year's 104.93 million EUR. The United States was the largest contributor to the company's revenue, accounting for 116.72 million EUR.
EarningsLife SciencesFinancial Markets
- Published
- 24 Jul 2026 22:41
- News subject
- Earnings
- Why this score
- No clear positive or negative phrase
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 0.1% · 20.4d old
- Duplicates
- 1 consolidated
#2443Tone
MedCity NewsDirect company coverageStored article
Priority Health Launches 2 Cancer Support Solutions with Color Health, Grail
Priority Health has partnered with Color Health and Grail to introduce two new cancer support solutions for self-funded employers. These solutions, available from January 1, 2027, will offer virtual cancer navigation, support, and multi-cancer early detection to Priority Health's 1.4 million members. The aim is to proactively address cancer earlier, provide personalized support, and potentially reduce healthcare costs associated with late-stage diagnoses.
Life SciencesFinance
- Published
- 24 Jul 2026 17:41
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 20.6d old
- Duplicates
- 1 consolidated
#2516Tone
lincolnjournal.comDirect company coverageStored article
GRAL Shareholder Alert: GRAIL, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm
The Gross Law Firm has issued a shareholder alert for investors of GRAIL, Inc. (GRAL), announcing a securities class action lawsuit. Investors who purchased GRAL shares between May 13, 2020, and February 19, 2026, are encouraged to contact the firm regarding potential lead plaintiff appointment. The lawsuit alleges that GRAIL defendants made misleading statements and concealed adverse facts about the company's NHS-Galleri trial results, leading to a significant stock price drop.
FinanceLife Sciences
- Published
- 24 Jul 2026 17:12
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk, Negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 2.1% · 20.6d old
- Duplicates
- 1 consolidated
#2644Tone
PR NewswireDirect company coverageStored article
HAGENS BERMAN, SOBOL SHAPIRO LLP ALERT: GRAIL, Inc. (NASDAQ: GRAL) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 4, 2026 Lead Plaintiff Deadline
Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) following a significant stock price drop. The lawsuit alleges that GRAIL and its executives misled investors about the clinical design and efficacy of its NHS-Galleri cancer screening trial, specifically regarding a three-year follow-up period that proved insufficient. Investors who purchased GRAL stock between May 13, 2025, and February 19, 2026, and incurred substantial losses, have until August 4, 2026, to seek lead plaintiff status.
FinanceFinancial MarketsLife Sciences
- Published
- 24 Jul 2026 12:12
- News subject
- Regulatory and legal
- Why this score
- Legal victory, Legal or regulatory risk
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 1.2% · 20.8d old
- Duplicates
- 3 consolidated
#2725Tone
GlobeNewswireDirect company coverageStored article
$GRAL Fraud Notification: GRAIL, Inc. Sued for Fraud Over Misrepresentations about its Trial Results – Investors Notified to Contact BFA Law
A securities fraud class action lawsuit has been filed against GRAIL, Inc. (NASDAQ:GRAL) due to a 50% stock dive following allegations that the company misrepresented results from its NHS-Galleri cancer trial. The lawsuit claims GRAIL misled investors regarding the trial's effectiveness and its ability to achieve its primary endpoint of reducing late-stage cancers within the stated three-year timeframe. Investors are encouraged to contact BFA Law to discuss their legal options, with a lead plaintiff deadline of August 4, 2026.
Life SciencesFinanceFinancial Markets
- Published
- 24 Jul 2026 10:12
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 1.7% · 20.9d old
- Duplicates
- 1 consolidated
#2837Tone
Stock Traders DailyDirect company coverageStored article
How Grail Inc Com (GRAL) Affects Rotational Strategy Timing
The article analyzes Grail Inc Com (GRAL) through a quantitative research lens, highlighting weak near-term sentiment that could precede shifts in its mid and long-term outlook. It identifies resistance levels and an exceptional short setup with significant downside potential against low risk. Several institutional trading strategies, including position, momentum, and risk hedging, are detailed along with multi-timeframe signal analysis to guide investors.
Financial MarketsLife Sciences
- Published
- 24 Jul 2026 03:10
- News subject
- Guidance
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 0.8% · 21.2d old
- Duplicates
- 1 consolidated
#2914Tone
The National Law ReviewDirect company coverageStored article
GRAL INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026
Faruqi & Faruqi, LLP reminds investors of a securities class action lawsuit against Grail, Inc. (GRAL) with a lead plaintiff deadline of August 4, 2026. The lawsuit alleges that Grail made misleading statements regarding the success of its NHS-Galleri cancer detection trial, which resulted in a significant stock price drop. Investors who purchased GRAL securities between May 13, 2025, and February 19, 2026, and suffered losses are encouraged to contact the law firm.
FinanceLife Sciences
- Published
- 24 Jul 2026 01:10
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk, Negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 2.1% · 21.2d old
- Duplicates
- 1 consolidated
#3021Tone
GlobeNewswireDirect company coverageStored article
Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) alleging violations of federal securities laws. The lawsuit claims that Grail and its officers made false and misleading statements regarding the likelihood of achieving the primary endpoint in the NHS-Galleri trial, thereby harming investors who purchased securities between May 13, 2025, and February 19, 2026. Investors are encouraged to join the lawsuit, with a lead plaintiff deadline of August 4, 2026.
FinanceLife Sciences
- Published
- 23 Jul 2026 16:09
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 1.7% · 21.6d old
- Duplicates
- 2 consolidated
Earlier company news
GRAL news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 15 older GRAL headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to GRAL, but the headline and available text are not mainly about GRAIL, LLC. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of GRAL sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.